Last 12 months
Inside the activity.
0 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 01:48 UTC |
Hohneker JohnDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,562 | $0.00 Strike: $31.74 | $0.00 |
DisclosureSEC source: 0001104659-26-076567 · tm2618519-2_4seq1.xml · derivative · entry 1 Hohneker John · CIK 0001695378 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,562 Underlying: Common Stock · 13,562 shares Expires 2036-06-17 F1 · derivative.exercise_date: The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 01:50 UTC |
Peterson KristineDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,562 | $0.00 Strike: $31.74 | $0.00 |
DisclosureSEC source: 0001104659-26-076569 · tm2618519-3_4seq1.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,562 Underlying: Common Stock · 13,562 shares Expires 2036-06-17 F1 · derivative.exercise_date: The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 01:46 UTC |
Nolet ChrisDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,562 | $0.00 Strike: $31.74 | $0.00 |
DisclosureSEC source: 0001104659-26-076566 · tm2618519-1_4seq1.xml · derivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,562 Underlying: Common Stock · 13,562 shares Expires 2036-06-17 F1 · derivative.exercise_date: The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 01:51 UTC |
Parsey MerdadDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,562 | $0.00 Strike: $31.74 | $0.00 |
DisclosureSEC source: 0001104659-26-076570 · tm2618519-4_4seq1.xml · derivative · entry 1 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,562 Underlying: Common Stock · 13,562 shares Expires 2036-06-17 F1 · derivative.exercise_date: The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 20:43 UTC |
Lutzker StuartDirector · President of R&D
|
GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $22.67 | $0.00 |
DisclosureSEC source: 0001104659-26-010477 · tm265104-3_4seq1.xml · derivative · entry 1 Lutzker Stuart · CIK 0002009257 · Director · President of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 20:44 UTC |
LaChapelle RobinChief Operating Officer
|
GrantStock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $22.67 | $0.00 |
DisclosureSEC source: 0001104659-26-010478 · tm265104-5_4seq1.xml · derivative · entry 1 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 20:41 UTC |
Kung WinstonChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $22.67 | $0.00 |
DisclosureSEC source: 0001104659-26-010473 · tm265104-2_4seq1.xml · derivative · entry 1 Kung Winston · CIK 0001666963 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 01:40 UTC |
Yao ZhengbinDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 550,000 | $0.00 Strike: $22.67 | $0.00 |
DisclosureSEC source: 0001104659-26-010472 · tm265104-4_4seq1.xml · derivative · entry 1 Yao Zhengbin · CIK 0001326228 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 20:39 UTC |
Kastenmayer James PaulGeneral Counsel
|
GrantStock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $22.67 | $0.00 |
DisclosureSEC source: 0001104659-26-010471 · tm265104-1_4seq1.xml · derivative · entry 1 Kastenmayer James Paul · CIK 0001798800 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| December 10, 2025 Filed Feb 3, 2026 21:05 UTC |
HHLR ADVISORS, LTD.10% owner
|
SaleCommon Stock | 555,555 | $23.37 | $12,983,320.35 |
DisclosureSEC source: 0000902664-26-000675 · ownership.xml · nonDerivative · entry 1 HILLHOUSE INVESTMENT MANAGEMENT, LTD. · CIK 0001510589 · 10% owner HHLR ADVISORS, LTD. · CIK 0001762304 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,929,117 F1 · shares: The securities reported herein were held by HACF, L.P., an exempted Cayman Islands limited partnership ("HACF"). HHLR (as defined below) acts as the sole management company of HACF. F2 · balance_after: The securities reported herein are held by VSUM VI Holdings Limited ("VSUM VI"), VSUM VIII Holdings Limited ("VSUM VIII") and ARVT Holdings Limited ("ARVT"). VSUM VI is a wholly owned subsidiary of Hillhouse Venture Fund V, L.P. ("Venture Fund V"), VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare Fund, L.P. ("Healthcare Fund") and ARVT is a wholly owned subsidiary of Hillhouse Venture Fund VI, L.P. ("Venture Fund VI"). HIM (as defined below) acts as the sole management company of each of Venture Fund V, Healthcare Fund and Venture Fund VI. F3 · ownership.nature: This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly. F4 · ownership.nature: The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 07:00 UTC |
LaChapelle RobinChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,503 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001104659-25-067928 · tm2520948-1_4seq1.xml · derivative · entry 7 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,370 Underlying: Common Stock · 6,503 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this option vested as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 07:00 UTC |
LaChapelle RobinChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,600 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001104659-25-067928 · tm2520948-1_4seq1.xml · derivative · entry 6 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,873 Underlying: Common Stock · 2,600 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this option vested as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 07:00 UTC |
LaChapelle RobinChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,050 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001104659-25-067928 · tm2520948-1_4seq1.xml · derivative · entry 5 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410 Underlying: Common Stock · 2,050 shares Expires 2031-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option vested as to 25% on September 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 07:00 UTC |
LaChapelle RobinChief Operating Officer
|
Exercise / conversionCommon Stock | 6,503 | $2.28 | $14,826.84 |
DisclosureSEC source: 0001104659-25-067928 · tm2520948-1_4seq1.xml · nonDerivative · entry 3 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 07:00 UTC |
LaChapelle RobinChief Operating Officer
|
Exercise / conversionCommon Stock | 2,600 | $2.28 | $5,928.00 |
DisclosureSEC source: 0001104659-25-067928 · tm2520948-1_4seq1.xml · nonDerivative · entry 2 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 07:00 UTC |
LaChapelle RobinChief Operating Officer
|
Exercise / conversionCommon Stock | 2,050 | $2.28 | $4,674.00 |
DisclosureSEC source: 0001104659-25-067928 · tm2520948-1_4seq1.xml · nonDerivative · entry 1 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 23:31 UTC |
Hohneker JohnDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,502 | $0.00 Strike: $24.89 | $0.00 |
DisclosureSEC source: 0001104659-25-061268 · tm2518583-2_4seq1.xml · derivative · entry 1 Hohneker John · CIK 0001695378 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,502 Underlying: Common Stock · 15,502 shares Expires 2035-06-17 Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 23:32 UTC |
Peterson KristineDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,502 | $0.00 Strike: $24.89 | $0.00 |
DisclosureSEC source: 0001104659-25-061269 · tm2518583-3_4seq1.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,502 Underlying: Common Stock · 15,502 shares Expires 2035-06-17 Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 23:29 UTC |
Nolet ChrisDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,502 | $0.00 Strike: $24.89 | $0.00 |
DisclosureSEC source: 0001104659-25-061267 · tm2518583-1_4seq1.xml · derivative · entry 1 Nolet Chris · CIK 0001782814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,502 Underlying: Common Stock · 15,502 shares Expires 2035-06-17 Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 23:33 UTC |
Parsey MerdadDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,502 | $0.00 Strike: $24.89 | $0.00 |
DisclosureSEC source: 0001104659-25-061270 · tm2518583-4_4seq1.xml · derivative · entry 1 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,502 Underlying: Common Stock · 15,502 shares Expires 2035-06-17 Read SEC document |
| April 28, 2025 Filed Apr 29, 2025 20:51 UTC |
Parsey MerdadDirector
|
GrantStock Option (right to buy) · Derivative | 28,346 | $0.00 Strike: $20.92 | $0.00 |
DisclosureSEC source: 0001104659-25-041344 · tm2513488-2_4seq1.xml · derivative · entry 1 Parsey Merdad · CIK 0001792150 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,346 Underlying: Common Stock · 28,346 shares Expires 2035-04-27 F1 · derivative.exercise_date: These options vest annually in equal installments over three years, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 03, 2025 Filed Feb 14, 2025 16:26 UTC |
Lutzker StuartDirector · President of R&D
|
GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $27.56 | $0.00 |
DisclosureSEC source: 0001104659-25-014172 · tm256714-4_4seq1.xml · derivative · entry 1 Lutzker Stuart · CIK 0002009257 · Director · President of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 3, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 03, 2025 Filed Feb 14, 2025 16:25 UTC |
LaChapelle RobinChief Operating Officer
|
GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $27.56 | $0.00 |
DisclosureSEC source: 0001104659-25-014170 · tm256714-3_4seq1.xml · derivative · entry 1 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 3, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 03, 2025 Filed Feb 14, 2025 16:24 UTC |
Kung WinstonChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $27.56 | $0.00 |
DisclosureSEC source: 0001104659-25-014164 · tm256714-2_4seq1.xml · derivative · entry 1 Kung Winston · CIK 0001666963 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 3, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 03, 2025 Filed Feb 14, 2025 21:27 UTC |
Yao ZhengbinDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 380,000 | $0.00 Strike: $27.56 | $0.00 |
DisclosureSEC source: 0001104659-25-014175 · tm256714-5_4seq1.xml · derivative · entry 1 Yao Zhengbin · CIK 0001326228 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,000 Underlying: Common Stock · 380,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 3, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 03, 2025 Filed Feb 14, 2025 16:23 UTC |
Kastenmayer James PaulGeneral Counsel
|
GrantStock Option (right to buy) · Derivative | 102,000 | $0.00 Strike: $27.56 | $0.00 |
DisclosureSEC source: 0001104659-25-014160 · tm256714-1_4seq1.xml · derivative · entry 1 Kastenmayer James Paul · CIK 0001798800 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,000 Underlying: Common Stock · 102,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 3, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| September 19, 2024 Filed Sep 23, 2024 18:14 UTC |
LaChapelle RobinChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,700 | $0.00 Strike: $6.24 | $0.00 |
DisclosureSEC source: 0001104659-24-102146 · tm2424588-1_4seq1.xml · derivative · entry 11 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,471 Underlying: Common Stock · 2,700 shares Expires 2033-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares underlying this option vested as to 25% on August 22, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| September 19, 2024 Filed Sep 23, 2024 18:14 UTC |
LaChapelle RobinChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 12,364 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001104659-24-102146 · tm2424588-1_4seq1.xml · derivative · entry 10 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,865 Underlying: Common Stock · 12,364 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this option vested as to 25% on February 1, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| September 19, 2024 Filed Sep 23, 2024 18:14 UTC |
LaChapelle RobinChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 7,164 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001104659-24-102146 · tm2424588-1_4seq1.xml · derivative · entry 9 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,473 Underlying: Common Stock · 7,164 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this option vested as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| September 19, 2024 Filed Sep 23, 2024 18:14 UTC |
LaChapelle RobinChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,867 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001104659-24-102146 · tm2424588-1_4seq1.xml · derivative · entry 8 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,637 Underlying: Common Stock · 2,867 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this option vested as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| September 19, 2024 Filed Sep 23, 2024 18:14 UTC |
LaChapelle RobinChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,471 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001104659-24-102146 · tm2424588-1_4seq1.xml · derivative · entry 7 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,460 Underlying: Common Stock · 2,471 shares Expires 2031-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option vested as to 25% on September 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| September 19, 2024 Filed Sep 23, 2024 18:14 UTC |
LaChapelle RobinChief Operating Officer
|
Exercise / conversionCommon Stock | 12,364 | $3.65 | $45,128.60 |
DisclosureSEC source: 0001104659-24-102146 · tm2424588-1_4seq1.xml · nonDerivative · entry 5 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2024 Filed Sep 23, 2024 18:14 UTC |
LaChapelle RobinChief Operating Officer
|
Exercise / conversionCommon Stock | 2,471 | $2.28 | $5,633.88 |
DisclosureSEC source: 0001104659-24-102146 · tm2424588-1_4seq1.xml · nonDerivative · entry 4 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2024 Filed Sep 23, 2024 18:14 UTC |
LaChapelle RobinChief Operating Officer
|
Exercise / conversionCommon Stock | 7,164 | $2.28 | $16,333.92 |
DisclosureSEC source: 0001104659-24-102146 · tm2424588-1_4seq1.xml · nonDerivative · entry 3 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2024 Filed Sep 23, 2024 18:14 UTC |
LaChapelle RobinChief Operating Officer
|
Exercise / conversionCommon Stock | 2,867 | $2.28 | $6,536.76 |
DisclosureSEC source: 0001104659-24-102146 · tm2424588-1_4seq1.xml · nonDerivative · entry 2 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2024 Filed Sep 23, 2024 18:14 UTC |
LaChapelle RobinChief Operating Officer
|
Exercise / conversionCommon Stock | 2,700 | $6.24 | $16,848.00 |
DisclosureSEC source: 0001104659-24-102146 · tm2424588-1_4seq1.xml · nonDerivative · entry 1 LaChapelle Robin · CIK 0002009136 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2024 Filed May 20, 2024 21:30 UTC |
Hohneker JohnDirector
|
GrantStock Option (right to buy) · Derivative | 29,550 | $0.00 Strike: $20.15 | $0.00 |
DisclosureSEC source: 0001104659-24-063518 · tm2414893-2_4seq1.xml · derivative · entry 1 Hohneker John · CIK 0001695378 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,550 Underlying: Common Stock · 29,550 shares Expires 2034-05-15 F1 · derivative.exercise_date: These options vest annually in equal installments over three years, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| April 22, 2024 Filed Apr 23, 2024 20:06 UTC |
Peterson KristineDirector
|
GrantStock Option (right to buy) · Derivative | 28,587 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001104659-24-050577 · tm2412470-2_4seq1.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,587 Underlying: Common Stock · 28,587 shares Expires 2034-04-21 F1 · derivative.exercise_date: These options vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:12 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VIII LLCDirector · 10% owner
OrbiMed Advisors IV LtdDirector · 10% owner
OrbiMed Asia GP IV, L.P.Director · 10% owner
|
ConversionSeries B Preferred Stock · Derivative | 469,615 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-008799 · tm244611-1_4seq1.xml · derivative · entry 10 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner OrbiMed Advisors IV Ltd · CIK 0001966835 · Director · 10% owner OrbiMed Asia GP IV, L.P. · CIK 0001966836 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 469,615 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis. F6 · derivative.exercise_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F6 · derivative.expiration_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, L.P. ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:12 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VIII LLCDirector · 10% owner
OrbiMed Advisors IV LtdDirector · 10% owner
OrbiMed Asia GP IV, L.P.Director · 10% owner
|
ConversionSeries B Preferred Stock · Derivative | 469,615 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-008799 · tm244611-1_4seq1.xml · derivative · entry 9 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner OrbiMed Advisors IV Ltd · CIK 0001966835 · Director · 10% owner OrbiMed Asia GP IV, L.P. · CIK 0001966836 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 469,615 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis. F6 · derivative.exercise_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F6 · derivative.expiration_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F2 · ownership.nature: These securities are held of record by OrbiMed Asia Partners IV, L.P. ("OAP IV"). OrbiMed Asia GP IV, L.P. ("Asia GP IV") is the general partner of OAP IV and OrbiMed Advisors IV Limited ("Advisors IV") is the general partner of Asia GP IV. OrbiMed Advisors LLC ("OrbiMed Advisors") is the advisory company of OAP IV. By virtue of such relationships, Asia GP IV, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OAP IV. F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:12 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VIII LLCDirector · 10% owner
OrbiMed Advisors IV LtdDirector · 10% owner
OrbiMed Asia GP IV, L.P.Director · 10% owner
|
ConversionSeries A Preferred Stock · Derivative | 821,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-008799 · tm244611-1_4seq1.xml · derivative · entry 8 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner OrbiMed Advisors IV Ltd · CIK 0001966835 · Director · 10% owner OrbiMed Asia GP IV, L.P. · CIK 0001966836 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 821,827 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis. F6 · derivative.exercise_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F6 · derivative.expiration_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, L.P. ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:12 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VIII LLCDirector · 10% owner
OrbiMed Advisors IV LtdDirector · 10% owner
OrbiMed Asia GP IV, L.P.Director · 10% owner
|
ConversionSeries A Preferred Stock · Derivative | 821,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-008799 · tm244611-1_4seq1.xml · derivative · entry 7 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner OrbiMed Advisors IV Ltd · CIK 0001966835 · Director · 10% owner OrbiMed Asia GP IV, L.P. · CIK 0001966836 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 821,827 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis. F6 · derivative.exercise_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F6 · derivative.expiration_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F2 · ownership.nature: These securities are held of record by OrbiMed Asia Partners IV, L.P. ("OAP IV"). OrbiMed Asia GP IV, L.P. ("Asia GP IV") is the general partner of OAP IV and OrbiMed Advisors IV Limited ("Advisors IV") is the general partner of Asia GP IV. OrbiMed Advisors LLC ("OrbiMed Advisors") is the advisory company of OAP IV. By virtue of such relationships, Asia GP IV, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OAP IV. F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:12 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VIII LLCDirector · 10% owner
OrbiMed Advisors IV LtdDirector · 10% owner
OrbiMed Asia GP IV, L.P.Director · 10% owner
|
PurchaseCommon Stock | 222,222 | $18.00 | $3,999,996.00 |
DisclosureSEC source: 0001104659-24-008799 · tm244611-1_4seq1.xml · nonDerivative · entry 6 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner OrbiMed Advisors IV Ltd · CIK 0001966835 · Director · 10% owner OrbiMed Asia GP IV, L.P. · CIK 0001966836 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,513,664 F5 · shares: Reflects shares purchased in the Issuer's initial public offering. F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, L.P. ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:12 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VIII LLCDirector · 10% owner
OrbiMed Advisors IV LtdDirector · 10% owner
OrbiMed Asia GP IV, L.P.Director · 10% owner
|
PurchaseCommon Stock | 222,222 | $18.00 | $3,999,996.00 |
DisclosureSEC source: 0001104659-24-008799 · tm244611-1_4seq1.xml · nonDerivative · entry 5 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner OrbiMed Advisors IV Ltd · CIK 0001966835 · Director · 10% owner OrbiMed Asia GP IV, L.P. · CIK 0001966836 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,513,664 F5 · shares: Reflects shares purchased in the Issuer's initial public offering. F2 · ownership.nature: These securities are held of record by OrbiMed Asia Partners IV, L.P. ("OAP IV"). OrbiMed Asia GP IV, L.P. ("Asia GP IV") is the general partner of OAP IV and OrbiMed Advisors IV Limited ("Advisors IV") is the general partner of Asia GP IV. OrbiMed Advisors LLC ("OrbiMed Advisors") is the advisory company of OAP IV. By virtue of such relationships, Asia GP IV, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OAP IV. F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:12 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VIII LLCDirector · 10% owner
OrbiMed Advisors IV LtdDirector · 10% owner
OrbiMed Asia GP IV, L.P.Director · 10% owner
|
ConversionCommon Stock | 469,615 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-008799 · tm244611-1_4seq1.xml · nonDerivative · entry 4 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner OrbiMed Advisors IV Ltd · CIK 0001966835 · Director · 10% owner OrbiMed Asia GP IV, L.P. · CIK 0001966836 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,291,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis. F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, L.P. ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:12 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VIII LLCDirector · 10% owner
OrbiMed Advisors IV LtdDirector · 10% owner
OrbiMed Asia GP IV, L.P.Director · 10% owner
|
ConversionCommon Stock | 469,615 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-008799 · tm244611-1_4seq1.xml · nonDerivative · entry 3 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner OrbiMed Advisors IV Ltd · CIK 0001966835 · Director · 10% owner OrbiMed Asia GP IV, L.P. · CIK 0001966836 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,291,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis. F2 · ownership.nature: These securities are held of record by OrbiMed Asia Partners IV, L.P. ("OAP IV"). OrbiMed Asia GP IV, L.P. ("Asia GP IV") is the general partner of OAP IV and OrbiMed Advisors IV Limited ("Advisors IV") is the general partner of Asia GP IV. OrbiMed Advisors LLC ("OrbiMed Advisors") is the advisory company of OAP IV. By virtue of such relationships, Asia GP IV, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OAP IV. F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:12 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VIII LLCDirector · 10% owner
OrbiMed Advisors IV LtdDirector · 10% owner
OrbiMed Asia GP IV, L.P.Director · 10% owner
|
ConversionCommon Stock | 821,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-008799 · tm244611-1_4seq1.xml · nonDerivative · entry 2 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner OrbiMed Advisors IV Ltd · CIK 0001966835 · Director · 10% owner OrbiMed Asia GP IV, L.P. · CIK 0001966836 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 821,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis. F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, L.P. ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:12 UTC |
ORBIMED ADVISORS LLCDirector · 10% owner
OrbiMed Capital GP VIII LLCDirector · 10% owner
OrbiMed Advisors IV LtdDirector · 10% owner
OrbiMed Asia GP IV, L.P.Director · 10% owner
|
ConversionCommon Stock | 821,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-008799 · tm244611-1_4seq1.xml · nonDerivative · entry 1 ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner OrbiMed Capital GP VIII LLC · CIK 0001845804 · Director · 10% owner OrbiMed Advisors IV Ltd · CIK 0001966835 · Director · 10% owner OrbiMed Asia GP IV, L.P. · CIK 0001966836 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 821,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis. F2 · ownership.nature: These securities are held of record by OrbiMed Asia Partners IV, L.P. ("OAP IV"). OrbiMed Asia GP IV, L.P. ("Asia GP IV") is the general partner of OAP IV and OrbiMed Advisors IV Limited ("Advisors IV") is the general partner of Asia GP IV. OrbiMed Advisors LLC ("OrbiMed Advisors") is the advisory company of OAP IV. By virtue of such relationships, Asia GP IV, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OAP IV. F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:11 UTC |
GORDON CARL LDirector · 10% owner
|
ConversionSeries B Preferred Stock · Derivative | 469,615 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-008797 · tm244611-3_4seq1.xml · derivative · entry 10 GORDON CARL L · CIK 0001282930 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 469,615 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis. F6 · derivative.exercise_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F6 · derivative.expiration_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, L.P. ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII. F4 · ownership.nature: Each of OrbiMed Advisors, GP VIII, Advisors IV, Asia GP IV, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| January 30, 2024 Filed Jan 31, 2024 21:11 UTC |
GORDON CARL LDirector · 10% owner
|
ConversionSeries B Preferred Stock · Derivative | 469,615 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-008797 · tm244611-3_4seq1.xml · derivative · entry 9 GORDON CARL L · CIK 0001282930 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 469,615 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis. F6 · derivative.exercise_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F6 · derivative.expiration_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F2 · ownership.nature: These securities are held of record by OrbiMed Asia Partners IV, L.P. ("OAP IV"). OrbiMed Asia GP IV, L.P. ("Asia GP IV") is the general partner of OAP IV and OrbiMed Advisors IV Limited ("Advisors IV") is the general partner of Asia GP IV. OrbiMed Advisors LLC ("OrbiMed Advisors") is the advisory company of OAP IV. By virtue of such relationships, Asia GP IV, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OAP IV. F4 · ownership.nature: Each of OrbiMed Advisors, GP VIII, Advisors IV, Asia GP IV, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.